Jonathan A L Duncan

Suggest Changes
Learn More
BACKGROUND The authors report on a prospective, randomized, placebo-controlled phase II trial to investigate avotermin (transforming growth factor beta-3) for reducing scarring resulting from acute(More)
  • 1